Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its ...

Novo Nordisk's diabetes medication, Ozempic, is one of 15 drugs set to enter Medicare price negotiations for the year 2027, ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...